

Corporate Income Tax Report

(EU Public Country by Country Report)

Fiscal Year 2025 (from January 1, 2025 to December 31, 2025)

In accordance with section First.4 of Additional Provision Eleven (hereinafter, AP 11th) of Law 22/2015, of July 20, Law on Auditing Accounts (hereinafter, LAC), the entity **Viatriis Pharmaceuticals, S.L.**, (hereinafter **Viatriis Pharmaceuticals**), headquartered at Calle General Aranz, número 86, 28037, Madrid (Madrid), subsidiary of **Viatriis Inc.**, is required to publish and make accessible a report regarding corporate tax or taxes of similar nature consolidated at the level of the ultimate parent company (EU public country by country report), given that:

- **Viatriis Pharmaceuticals** is an entity subject to Spanish law, considered a medium or large-sized entity, according to the thresholds set out in Article 3 of the LAC, and
- **Viatriis Inc.** is the ultimate parent company, not governed by the law of an EU Member State. The net consolidated annual turnover of the group at the end of the fiscal year exceeded a total of 750,000,000 euros in each of the last two consecutive fiscal years according to its consolidated financial statements.

To comply with this obligation, Viatriis Pharmaceuticals has requested Viatriis Inc. to provide all the information required by the 11th Additional Provision of the LAC. However, this information has not been made available to Viatriis Pharmaceuticals because the group information was not yet available at the time of preparing and filing the Annual Accounts of this entity.

Therefore, Viatriis Pharmaceuticals has prepared the report on corporate tax required by the 11th Additional Provision of the LAC, considering only the information of Viatriis Group in Spain, available at the time of filing its Annual Accounts for the fiscal year 2025, without prejudice to the fact that the definitive information will be included in the report on corporate tax of the entire group that will be published by Viatriis Inc. in another EU Member State, within the 12-month period provided for in Directive 2021/2101, which amended Directive 2013/34/EU as regards disclosure of income tax information by certain undertakings and branches.

Content of the Corporate Income Tax Report

Section 1. General information

Name of the ultimate parent of the group / of the standalone undertaking	Viatrix Inc
Country where the ultimate parent has its registered office	United States of America
Financial Year – start date	01/01/2025
Financial Year – end date	31/12/2025
Reporting currency	EUR
Is the information in the report based on reporting instructions used for tax purposes, pursuant to Section III, Part B and C, of Annex III to Directive 2011/16/EU (yes/no)?	Yes

Section 2. Overview of information on a country-by-country basis (no information has been omitted)

Tax jurisdiction	Currency ¹	Country code	Revenues	Profit (loss) before income tax	Income tax paid – on cash basis	Income tax accrued – current year	Accumulated earnings	Number of employees
Spain	USD	SP	381,262,018	53,803,262	12,910,215	6,281,236	112,248,355	432
Spain	EUR	SP	338,057,056	47,706,227	11,447,218	5,569,441	95,563,086	432

Section 3. List of subsidiaries and activities

Member States or tax jurisdiction	Country code	Name of each subsidiary undertaking in the Member State or tax jurisdiction	Brief description of the nature of activities in the Member State or tax jurisdiction
Spain	SP	Viatrix Pharmaceuticals Sociedad Limitada	Sales, Marketing or Distribution
		Meda Pharma Sociedad Limitada	Other
		Fundación Viatrix para la Salud	Dormant

This report has been filed in the Mercantile Register of Madrid.

¹ The exchange rate applied is, on the one hand, the group average rate (0.8867) for profit and loss items, and, on the other hand, the group closing rate (0.8514) for balance sheet items.